Cargando…
Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review
The optimal dose of recombinant tissue plasminogen activator (rtPA) for acute ischaemic stroke (AIS) remains controversial, especially in Asian countries. We aimed to update the evidence regarding the use of low-dose versus standard-dose rtPA. We performed a systematic literature search across MEDLI...
Autores principales: | Wang, Xia, You, Shoujiang, Sato, Shoichiro, Yang, Jie, Carcel, Cheryl, Zheng, Danni, Yoshimura, Sohei, Anderson, Craig S, Sandset, Else Charlotte, Robinson, Thompson, Chalmers, John, Sharma, Vijay K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870642/ https://www.ncbi.nlm.nih.gov/pubmed/29600005 http://dx.doi.org/10.1136/svn-2017-000112 |
Ejemplares similares
-
Baseline brain imaging signs in patients with ischaemic stroke by the presence of atrial fibrillation: the ENCHANTED trial
por: Wang, Xia, et al.
Publicado: (2023) -
Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis
por: You, Shoujiang, et al.
Publicado: (2018) -
Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?
por: Dong, Yi, et al.
Publicado: (2016) -
Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial
por: Zhou, Zien, et al.
Publicado: (2021) -
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
por: Wardlaw, Joanna M, et al.
Publicado: (2012)